Presentation is loading. Please wait.

Presentation is loading. Please wait.

Immunohistochemistry is a Reliable Screening Tool for Identification of ALK Rearrangement in Non–Small-Cell Lung Carcinoma and is Antibody Dependent 

Published byUtami Tan Modified over 5 years ago

Similar presentations

Presentation on theme: "Immunohistochemistry is a Reliable Screening Tool for Identification of ALK Rearrangement in Non–Small-Cell Lung Carcinoma and is Antibody Dependent "— Presentation transcript:

1 Immunohistochemistry is a Reliable Screening Tool for Identification of ALK Rearrangement in Non–Small-Cell Lung Carcinoma and is Antibody Dependent  Chris M.J. Conklin, MD, Kenneth J. Craddock, MD, Cherry Have, BSc, MLT, Janessa Laskin, MD, Christian Couture, MD, Diana N. Ionescu, MD  Journal of Thoracic Oncology  Volume 8, Issue 1, Pages (January 2013) DOI: /JTO.0b013e318274a83e Copyright © 2012 International Association for the Study of Lung Cancer Terms and Conditions

2 FIGURE 1 Semiquantitative immunohistochemical staining using an antibody to ALK (D5F3 by Cell Signaling [Billerica, MA] with ADVANCE detection), 400x original magnification. A, IHC score 3+ showing intense granular cytoplasmic staining. B, IHC score 2+ showing moderate smooth cytoplasmic staining (without granularity seen in score 3+). C, IHC score 1+ showing faint, barely discernible cytoplasmic staining in any tumor cells. D, IHC score 0/negative showing no staining. ALK, anaplastic lymphoma receptor tyrosine kinase; IHC, immunohistochemistry Journal of Thoracic Oncology 2013 8, 45-51DOI: ( /JTO.0b013e318274a83e) Copyright © 2012 International Association for the Study of Lung Cancer Terms and Conditions

3 FIGURE 2 Dual-color break-apart FISH performed using the commercially available ALK probe (Vysis LSI ALK Dual Color, Break Apart Rearrangement Probe, Abbott Molecular, Abbott, IL) on case 11. ALK break-apart FISH showed a straightforward break-apart signal configuration (1 red, 1 green, 1 fusion [1R1G1F]) in 51% of the nuclei, indicating ALK rearrangement. Splitting of the red and green signals (shown with arrows) indicates ALK rearrangement. ALK, anaplastic lymphoma receptor tyrosine kinase; NSCLC, non–small-cell lung carcinoma; FISH, fluorescence in situ hybridization. Journal of Thoracic Oncology 2013 8, 45-51DOI: ( /JTO.0b013e318274a83e) Copyright © 2012 International Association for the Study of Lung Cancer Terms and Conditions

4 FIGURE 3 Diagnostic screening algorithm using ALK-immunohistochemistry (5A4 by Novocastra or D5F3 by Cell Signaling with ADVANCE detection), and FISH for confirmation in NSCLC. Only cases showing any degree of ALK-expression by IHC are tested by FISH. ALK, anaplastic lymphoma receptor tyrosine kinase; FISH, fluorescence in situ hybridization; NSCLC, non–small-cell lung cancer; IHC, immunohistochemistry. Journal of Thoracic Oncology 2013 8, 45-51DOI: ( /JTO.0b013e318274a83e) Copyright © 2012 International Association for the Study of Lung Cancer Terms and Conditions

Download ppt "Immunohistochemistry is a Reliable Screening Tool for Identification of ALK Rearrangement in Non–Small-Cell Lung Carcinoma and is Antibody Dependent "

Similar presentations

Fig. 1. EGFR content as determined by fluorescence in situ hybridization (FISH) and immunohistochemical staining. FISH was performed with the EGFR ( red.

Fig. 1. EGFR content as determined by fluorescence in situ hybridization (FISH) and immunohistochemical staining. FISH was performed with the EGFR ( red.
Naomi Fujioka, MD, Christopher A. French, MD, Michael J

Naomi Fujioka, MD, Christopher A. French, MD, Michael J
Transthoracic needle biopsy of lung adenocarcinoma: all tumour cells are stained with 5A4 clone (anaplastic lymphoma kinase (ALK) immunohistochemistry.

Transthoracic needle biopsy of lung adenocarcinoma: all tumour cells are stained with 5A4 clone (anaplastic lymphoma kinase (ALK) immunohistochemistry.
Is Cytology Reliable for Epidermal Growth Factor Receptor Gene Evaluation in Non- small Cell Lung Cancer?  Cecilia Bozzetti, PhD, Marcello Tiseo, MD, Costanza.

Is Cytology Reliable for Epidermal Growth Factor Receptor Gene Evaluation in Non- small Cell Lung Cancer?  Cecilia Bozzetti, PhD, Marcello Tiseo, MD, Costanza.
Detection of TMPRSS2-ETS Fusions by a Multiprobe Fluorescence in Situ Hybridization Assay for the Early Diagnosis of Prostate Cancer  Qi-Peng Sun, Liao-Yuan.

Detection of TMPRSS2-ETS Fusions by a Multiprobe Fluorescence in Situ Hybridization Assay for the Early Diagnosis of Prostate Cancer  Qi-Peng Sun, Liao-Yuan.
ALK Protein Analysis by IHC Staining after Recent Regulatory Changes: A Comparison of Two Widely Used Approaches, Revision of the Literature, and a New.

ALK Protein Analysis by IHC Staining after Recent Regulatory Changes: A Comparison of Two Widely Used Approaches, Revision of the Literature, and a New.
Canadian Anaplastic Lymphoma Kinase Study: A Model for Multicenter Standardization and Optimization of ALK Testing in Lung Cancer  Jean-Claude Cutz, MD,

Canadian Anaplastic Lymphoma Kinase Study: A Model for Multicenter Standardization and Optimization of ALK Testing in Lung Cancer  Jean-Claude Cutz, MD,
Detection of ALK Gene Rearrangement in Non-small Cell Lung Cancer: A Comparison of Fluorescence In Situ Hybridization and Chromogenic In Situ Hybridization.

Detection of ALK Gene Rearrangement in Non-small Cell Lung Cancer: A Comparison of Fluorescence In Situ Hybridization and Chromogenic In Situ Hybridization.
Detection of TMPRSS2-ETS Fusions by a Multiprobe Fluorescence in Situ Hybridization Assay for the Early Diagnosis of Prostate Cancer  Qi-Peng Sun, Liao-Yuan.

Detection of TMPRSS2-ETS Fusions by a Multiprobe Fluorescence in Situ Hybridization Assay for the Early Diagnosis of Prostate Cancer  Qi-Peng Sun, Liao-Yuan.
New Methods for ALK Status Diagnosis in Non–Small-Cell Lung Cancer: An Improved ALK Immunohistochemical Assay and a New, Brightfield, Dual ALK IHC–In.

New Methods for ALK Status Diagnosis in Non–Small-Cell Lung Cancer: An Improved ALK Immunohistochemical Assay and a New, Brightfield, Dual ALK IHC–In.
Detection of Rearrangements and Transcriptional Up-Regulation of ALK in FFPE Lung Cancer Specimens Using a Novel, Sensitive, Quantitative Reverse Transcription.

Detection of Rearrangements and Transcriptional Up-Regulation of ALK in FFPE Lung Cancer Specimens Using a Novel, Sensitive, Quantitative Reverse Transcription.
EGFR Status in Mesothelioma: Possible Implications for the Efficacy of Anti-EGFR and Anti-MET Therapies  Sandra Salvi, PhD, Serena Varesano, PhD, Simona.

EGFR Status in Mesothelioma: Possible Implications for the Efficacy of Anti-EGFR and Anti-MET Therapies  Sandra Salvi, PhD, Serena Varesano, PhD, Simona.
Next-Generation Sequencing Identifies and Immunohistochemistry Confirms a Novel Crizotinib-Sensitive ALK Rearrangement in a Patient with Metastatic Non–Small-Cell.

Next-Generation Sequencing Identifies and Immunohistochemistry Confirms a Novel Crizotinib-Sensitive ALK Rearrangement in a Patient with Metastatic Non–Small-Cell.
ALK FISH and IHC: You Cannot Have One without the Other

ALK FISH and IHC: You Cannot Have One without the Other
Cases of ALK-Rearranged Lung Cancer with 5-Year Progression-Free Survival with Crizotinib as Initial Precision Therapy  Deepa Rangachari, MD, Xiuning.

Cases of ALK-Rearranged Lung Cancer with 5-Year Progression-Free Survival with Crizotinib as Initial Precision Therapy  Deepa Rangachari, MD, Xiuning.
Heterogeneity of Anaplastic Lymphoma Kinase Gene Rearrangement in Non–Small-Cell Lung Carcinomas: A Comparative Study Between Small Biopsy and Excision.

Heterogeneity of Anaplastic Lymphoma Kinase Gene Rearrangement in Non–Small-Cell Lung Carcinomas: A Comparative Study Between Small Biopsy and Excision.
Jessica J. Lin, MD, Lauren L. Ritterhouse, MD, PhD, Siraj M

Jessica J. Lin, MD, Lauren L. Ritterhouse, MD, PhD, Siraj M
Transformation to Sarcomatoid Carcinoma in ALK-Rearranged Adenocarcinoma, Which Developed Acquired Resistance to Crizotinib and Received Subsequent Chemotherapies 

Transformation to Sarcomatoid Carcinoma in ALK-Rearranged Adenocarcinoma, Which Developed Acquired Resistance to Crizotinib and Received Subsequent Chemotherapies 
FISH Analysis of Crizotinib Target Genes ROS1/ALK/MET in Malignant Mesothelioma  Sandra Salvi, PhD, Serena Varesano, PhD, Simona Boccardo, PhD, Jean Louis.

FISH Analysis of Crizotinib Target Genes ROS1/ALK/MET in Malignant Mesothelioma  Sandra Salvi, PhD, Serena Varesano, PhD, Simona Boccardo, PhD, Jean Louis.
Clinicopathologic Analysis of ROS1-Rearranged Non–Small-Cell Lung Cancer and Proposal of a Diagnostic Algorithm  Heounjeong Go, MD, PhD, Dong-Wan Kim,

Clinicopathologic Analysis of ROS1-Rearranged Non–Small-Cell Lung Cancer and Proposal of a Diagnostic Algorithm  Heounjeong Go, MD, PhD, Dong-Wan Kim,

Similar presentations

Ads by Google